Susanna Akiki

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 836 citations · Full text

Medicine, Hematology, Molecular Genetics +16

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Ana Rio‐Machín, Tom Vulliamy, Nele Hug et al. · Nature Communications · 2020 · 116 citations · Full text

Life Sciences, Genetics, Hematology +17

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

Jelena Jovanović, Adam Ivey, Alessandro M. Vannucchi et al. · Leukemia · 2013 · 106 citations · Full text

Medicine, Hematology, Molecular Biology +15

Molecular diagnosis of the myeloproliferative neoplasms: <scp>UK</scp> guidelines for the detection of <i><scp>JAK</scp>2 </i><scp>V</scp>617<scp>F</scp> and other relevant mutations

Anthony J. Bench, Helen White, Letizia Foroni et al. · British Journal of Haematology · 2012 · 94 citations · Full text

Medicine, Hematology, Molecular Medicine +17

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

Helen White, Liesbet Deprez, Philippe Corbisier et al. · Leukemia · 2014 · 81 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +13